Earlier this week, Human Genome Sciences Inc. (HGSI) announced that its eagerly anticipated lupus drug Benlysta is expected to cost patients about $20,000 a year. The actual price might also be slightly more than the figure. Consequently, the drug could reach $1 billion in annual sales if taken by 50,000 patients, which represents a small fraction of those affected by the disease. In July 2009, Human Genome Sciences and GlaxoSmithKline PLC (GSK) announced that Benlysta met the primary endpoint in BLISS-52, the first of two pivotal phase III trials in patients with serologically active systemic lupus erythematosus (SLE). In the placebo-controlled BLISS-52 study, the results showed that Benlysta plus standard of care achieved a clinically and statistically significant improvement in patient response rate at Week 52 compared with standard of care alone. Study results also showed that Benlysta was generally well tolerated, with adverse ...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Wednesday September 16, 2009

DrStockPick.com Stock Report!

**************************************************************

Celebrating the stories, culture and heritage of America’s Deaf and Hard-of-Hearing Community, Purple Communications, Inc. (Nasdaq: PRPL) will honor National Champion Motocross Rider and Floridian, Ashley Fiolek for being a role model to deaf youth nationwide and her accomplishments as a stellar athlete in a male-dominated sport. Community members are encouraged to join in the celebration on September 19, 2009 at the Hilton St. Petersburg Carillon Park, 950 Lake Carillon Drive in Saint Petersburg, FL. The event will feature

...

Maxygen, Inc. (NASDAQ: MAXY) is committed to developing superior versions of existing major protein pharmaceuticals. The company’s lead product candidates meet the demands of substantial market opportunities such as cancer and autoimmune diseases. Well positioned for growth, Maxygen has a number of promising product candidates and the financial strength required to drive them through clinical development.

Maxygen currently has three protein pharmaceuticals advancing towards clinical development. Behind its product candidates, the company has developed a broad pipeline of other human therapeutics products that are in earlier stages of development. In addition to these, Maxygen also believes its proprietary technologies could transform the design and development of vaccines.

The company’s MAXY-G34 product candidate was designed to be an improved next-generation granulocyte colony stimulating factor for the treatment of neutropenia, a severe decrease in neutrophil cell counts in the blood. MAXY-G34 may help the body make white blood cells more quickly than the

...

We await the outcome of the US Food and Drug Administration’s (FDA) advisory panel meeting scheduled for today that will decide on various aspects of human papillomavirus (HPV) vaccines. Primarily there are two vaccines available for the prevention of cervical cancer in women -- Merck’s (MRK) Gardasil and GlaxoSmithKline’s (GSK) Cervarix. Both vaccines are given in a series of three shots over a six-month period. Although Cervarix is approved in several countries, it has yet to gain FDA approval. In June 2006, the FDA approved the first cervical cancer vaccine, Gardasil (which targets four HPV strains: HPV 6, HPV 11, HPV 16 and HPV 18) for females 9 to 26 years of age. The FDA panel will decide on the approval of Cervarix (targets two HPV strains, HPV 16 and HPV 18) in females 10 to 25 years of age. In addition, the vaccine ...

CRWENewswire.com is pleased to announce a stock highlight on American International Group, Inc. (AIG), Opexa Therapeutics, Inc. (NASDAQ:OPXA), NYSE Euronext (NYX)

American International Group, Inc. (AIG) today reported its first quarterly profit since the third quarter of 2007, as certain of its businesses stabilized and the company’s results reflected positive valuation changes. AIG also achieved several important milestones in its restructuring program. For the second quarter ended June 30, 2009, AIG reported net income attributable to AIG of $1.8 billion, including net income attributable to AIG common shareholders of $311 million or $2.30 per diluted common share, compared with a net loss of $5.4 billion or $41.13 per diluted share in the second quarter of 2008. Second quarter 2009 adjusted net income was $2.0 billion, compared with an adjusted net loss of $1.3 billion in the second quarter of 2008.

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell immunotherapy for

...

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

 

Tuesday August 4, 2009

PennyOmega.com Stock Report!

**************************************************************

Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the closing of its previously announced public offering of 14,000,000 shares of common stock. Micromet also announced that the underwriters for the offering have exercised in full their over-allotment option to purchase an additional 2,100,000 shares, bringing the total shares sold to 16,100,000 at a price of $5.00 per share for gross proceeds of $80.5 million. The Company received net proceeds of approximately $75.0 million, after deducting underwriting discounts and estimated offering expenses.

The Board of Directors of

...

DrStockPick.com Stock Report!

Monday August 3, 2009

**************************************************************

Acorn Energy, Inc. (Nasdaq: ACFN) today announced that it expects to report for the second quarter ended June 30, 2009, revenue of approximately $7.8 million, an increase of 116% from $3.6 million in the comparable quarter last year. In addition, the Company is estimating Q2 2009 gross profit of $3.5 million versus $1.0 million in Q1 2008, which represents the effects of increased revenues and an expected improvement in gross margins from 29% to 45%.

Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it has received Orphan Drug Designation from the European Medicines Agency (EMEA) for BiTE antibody blinatumomab (MT103) for acute

...

In June, the World Health Organization (WHO) alerted the public that a worldwide pandemic of swine flu (H1N1) was sweeping the globe.  Health officials at the Centers for Disease Control and Prevention (CDC) have stated that the swine flu virus could infect up to 40% of Americans over the next couple of years.  At last count, the CDC said there are 43,771 swine flu cases that have been reported in America, and 302 deaths have been associated with the disease.

Many medical experts say that washing your hands with soap and water or an alcohol–based hand sanitizer are the most effective means of minimizing the spread of the swine flu.

I have been researching a small company focused on the development of pharmaceuticals for the treatment of cancer, cardiovascular, autoimmune diseases and viral infections.  BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is presently conducting trials for a new flu treatment called Peramivir that is said

...

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

 

Thursday July 30, 2009

PennyOmega.com Stock Report!

**************************************************************

Senomyx, Inc. (Nasdaq: SNMX) will release its second quarter 2009 financial results on Tuesday, August 4, 2009 before the opening of the U.S. financial markets. The Company will also host a conference call with a live Internet broadcast that will provide a corporate update and a review of its second quarter results on the same day at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time).

Appalachian Bancshares, Inc. (Nasdaq:APAB), holding company for Appalachian Community Bank, Appalachian Community Bank, F.S.B., and Appalachian Real Estate Holdings, Inc. reported consolidated total assets of $1.2 billion, at June 30, 2009, compared to $1.1 billion

...

HGSI’s Benlysta meets its endpoints in Bliss-52 phase III trial for lupus Earlier today, Human Genome Sciences, Inc. (HGSI) and GlaxoSmithKline PLC (GSK) announced that Benlysta met the primary endpoint in BLISS-52, the first of two pivotal phase III trials in patients with serologically active systemic lupus erythematosus (SLE). In the placebo-controlled BLISS-52 study, the results showed that Benlysta plus standard of care achieved a clinically and statistically significant improvement in patient response rate at Week 52 compared with standard of care alone. Study results also showed that Benlysta was generally well tolerated, with adverse event rates comparable between belimumab and placebo treatment groups. As a reminder, HGSI and GSK is co-developing Benlysta as a potential treatment for SLE. Benlysta is a human monoclonal antibody that specifically recognizes and inhibits the biological activity of B-lymphocyte stimulator (BLyS). BLyS is a naturally occurring protein discovered ...